Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradiscal rhGDF-5 for Early Stage Lumbar Disc Degeneration
NCT01124006Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 2010
- Primary completion
- Sep 2014
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gdf5 in degenerative disc disease (DDD) (2 arms), sponsored by Johnson & Johnson. Primary endpoints: Neurological Assessment for Motor Function and Reflexes/Sensory at 12 months and Treatment Emergent Adverse Events- Relationship to Study Drug at 36 months. Started Jan 2010; status: completed.
02
Drugs
gdf5
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT01124006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01124006.